Do you want to read an article? Please log in or register.
A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention
Lipid-Lowering Drugs
Related content
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines
JAMA.
Pagidipati NJ, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ
doi: 10.1001/jama.2017.3416.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up
Circulation.
Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK
doi: 10.1161/
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering DrugsMyocardial Infarction
Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry
J Am Coll Cardiol.
Singh A, Collins BL, Gupta A, Fatima A, Qamar A, Biery D, Baez J, Cawley M, Klein J, Hainer J, Plutzky J, Cannon CP, Nasir K, Di Carli MF, Bhatt DL, Blankstein R
doi: 10.1016/j.jacc.2017.11.007.
RECOMMENDED
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circ Cardiovasc Qual Outcomes
Saeed A, Zhu J, Thoma F, Marroquin O, Aiyer A, Agarwala A, Virani SS, Gulati M, Lee JS, Reis S, Saba S, Ballantyne C, Mulukutla S
doi: 10.1161/CIRCOUTCOMES.120.007485
Myocardial InfarctionThrombosis and StrokeTherapy and Intervention
Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study
Lancet.
Li L, Geraghty OC, Mehta Z, Rothwell PM; Oxford Vascular Study
doi: 10.1016/S0140-
Cardiovascular Risk and Diseases
Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus
J Am Heart Assoc
Malmborg M, Schmiegelow MDS, Gerds T, Schou M, Kistorp C, Torp-Pedersen C, Gislason G
doi: 10.1161/JAHA.120.020395
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease
Eur Heart J.
Mortensen MB, Nordestgaard BG
doi: 10.1093/eurheartj/ehaa150.
Cardiovascular Risk and Diseases
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT
Circulation.
Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park JG, White JA, Bohula E, Braunwald E; IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators
doi: 10.1161/CIRCULATIONAHA.
COMMENTED
Lipid-Lowering Drugs
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants
Am Heart J.
Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA
doi: 10.1016/j.ahj.2018.12.007.